TP53 and non-small cell lung carcinoma: As a matter of fact, the survival of p53 LOH(+); hDMP1 LOH(+) was comparable to or even better than that of p53 LOH(-) in UM samples (p = 0.0013, χ2 = 13.2841 in PFS; p = 0.0012, χ2 = 13.5258 in TS, triple survival assay), indicating that one locus hDMP1 deletion neutralized the negative effect of p53 LOH in NSCLC (3000 day survival of 12.0% became 87.5% in PFS (7.3 fold improvement), Figure 2A; 3000 day survival of 19.8% became 87.5% in TS (4.2 fold), Figure 2B).